Literature DB >> 28681133

Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.

Sanjiv J Shah1.   

Abstract

A major challenge in the care of patients with heart failure and preserved ejection fraction (HFpEF) is the lack of proven therapies due to disappointing results from randomized controlled trials (RCTs). The heterogeneity of the HFpEF syndrome and the use of conventional RCT designs are possible reasons underlying the failure of these trials. There are several factors-including the widespread adoption of electronic health records, decreasing costs of obtaining high-dimensional data, and the availability of a wide variety of potential therapeutics-that have evolved to enable more innovative clinical trial designs in HFpEF. Here, we review the current landscape of HFpEF RCTs and present several innovative RCT designs that could be implemented in HFpEF, including enrichment trials, adaptive trials, umbrella trials, basket trials, and machine learning-based trials (including examples for each). Our hope is that the description of the aforementioned innovative trial designs will stimulate new approaches to clinical trials in HFpEF.

Entities:  

Keywords:  Clinical trials; Heart failure with preserved ejection fraction; Personalized medicine; Precision medicine; Treatment

Mesh:

Year:  2017        PMID: 28681133      PMCID: PMC5571647          DOI: 10.1007/s12265-017-9759-8

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  59 in total

1.  Personalized Nutrition by Prediction of Glycemic Responses.

Authors:  David Zeevi; Tal Korem; Niv Zmora; David Israeli; Daphna Rothschild; Adina Weinberger; Orly Ben-Yacov; Dar Lador; Tali Avnit-Sagi; Maya Lotan-Pompan; Jotham Suez; Jemal Ali Mahdi; Elad Matot; Gal Malka; Noa Kosower; Michal Rein; Gili Zilberman-Schapira; Lenka Dohnalová; Meirav Pevsner-Fischer; Rony Bikovsky; Zamir Halpern; Eran Elinav; Eran Segal
Journal:  Cell       Date:  2015-11-19       Impact factor: 41.582

2.  Mastering the game of Go with deep neural networks and tree search.

Authors:  David Silver; Aja Huang; Chris J Maddison; Arthur Guez; Laurent Sifre; George van den Driessche; Julian Schrittwieser; Ioannis Antonoglou; Veda Panneershelvam; Marc Lanctot; Sander Dieleman; Dominik Grewe; John Nham; Nal Kalchbrenner; Ilya Sutskever; Timothy Lillicrap; Madeleine Leach; Koray Kavukcuoglu; Thore Graepel; Demis Hassabis
Journal:  Nature       Date:  2016-01-28       Impact factor: 49.962

3.  Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).

Authors:  Benjamin W Van Tassell; Leo F Buckley; Salvatore Carbone; Cory R Trankle; Justin M Canada; Dave L Dixon; Nayef Abouzaki; Claudia Oddi-Erdle; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate
Journal:  Clin Cardiol       Date:  2017-05-05       Impact factor: 2.882

Review 4.  Lorcaserin Hcl for the treatment of obesity.

Authors:  Alpana P Shukla; Rekha B Kumar; Louis J Aronne
Journal:  Expert Opin Pharmacother       Date:  2015-10-15       Impact factor: 3.889

5.  The HFpEF Obesity Phenotype: The Elephant in the Room.

Authors:  Dalane W Kitzman; Sanjiv J Shah
Journal:  J Am Coll Cardiol       Date:  2016-07-12       Impact factor: 24.094

Review 6.  Metformin as a Tool to Target Aging.

Authors:  Nir Barzilai; Jill P Crandall; Stephen B Kritchevsky; Mark A Espeland
Journal:  Cell Metab       Date:  2016-06-14       Impact factor: 27.287

Review 7.  Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade.

Authors:  C Noel Bairey Merz; Carl J Pepine; Mary Norine Walsh; Jerome L Fleg
Journal:  Circulation       Date:  2017-03-14       Impact factor: 29.690

8.  Pragmatic Trials.

Authors:  Ian Ford; John Norrie
Journal:  N Engl J Med       Date:  2016-08-04       Impact factor: 91.245

9.  PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.

Authors:  M R Trusheim; A A Shrier; Z Antonijevic; R A Beckman; R K Campbell; C Chen; K T Flaherty; J Loewy; D Lacombe; S Madhavan; H P Selker; L J Esserman
Journal:  Clin Pharmacol Ther       Date:  2016-10-19       Impact factor: 6.875

10.  Three simple rules to ensure reasonably credible subgroup analyses.

Authors:  James F Burke; Jeremy B Sussman; David M Kent; Rodney A Hayward
Journal:  BMJ       Date:  2015-11-04
View more
  14 in total

Review 1.  Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.

Authors:  Sanjiv J Shah
Journal:  J Cardiovasc Transl Res       Date:  2017-06-05       Impact factor: 4.132

Review 2.  Contemporary Review of Risk Scores in Prediction of Coronary and Cardiovascular Deaths.

Authors:  Jose B Cruz Rodriguez; Khan O Mohammad; Haider Alkhateeb
Journal:  Curr Cardiol Rep       Date:  2022-01-27       Impact factor: 2.931

Review 3.  The future of heart failure with preserved ejection fraction : Deep phenotyping for targeted therapeutics.

Authors:  Frank R Heinzel; Sanjiv J Shah
Journal:  Herz       Date:  2022-06-29       Impact factor: 1.740

Review 4.  Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary.

Authors:  Sanjiv J Shah; Barry A Borlaug; Dalane W Kitzman; Andrew D McCulloch; Burns C Blaxall; Rajiv Agarwal; Julio A Chirinos; Sheila Collins; Rahul C Deo; Mark T Gladwin; Henk Granzier; Scott L Hummel; David A Kass; Margaret M Redfield; Flora Sam; Thomas J Wang; Patrice Desvigne-Nickens; Bishow B Adhikari
Journal:  Circulation       Date:  2020-03-23       Impact factor: 29.690

5.  Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials.

Authors:  Ravi B Patel; Sanjiv J Shah
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-10-08       Impact factor: 13.820

6.  20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicine-Digital Biopsy to Deconstruct Biology.

Authors:  Sanjiv J Shah
Journal:  J Am Soc Echocardiogr       Date:  2019-11       Impact factor: 5.251

7.  Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial.

Authors:  Gavin A Lewis; Susanna Dodd; Dannii Clayton; Emma Bedson; Helen Eccleson; Erik B Schelbert; Josephine H Naish; Beatriz Duran Jimenez; Simon G Williams; Colin Cunnington; Fozia Zahir Ahmed; Anne Cooper; Stuart Russell; Theresa McDonagh; Paula R Williamson; Christopher A Miller
Journal:  Nat Med       Date:  2021-08-12       Impact factor: 53.440

Review 8.  Innovative highlights of clinical drug trial design.

Authors:  Daohong Chen; Eric Yining Qi
Journal:  Transl Res       Date:  2020-06-03       Impact factor: 7.012

9.  Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: Beyond EROOM's Law.

Authors:  Gail A Van Norman
Journal:  JACC Basic Transl Sci       Date:  2017-10-30

10.  Meta-Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction.

Authors:  Jonathan D Rich; Jacob Burns; Benjamin H Freed; Mathew S Maurer; Daniel Burkhoff; Sanjiv J Shah
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.